Michael Pears
With almost 20 years’ experience in biotechnology and life sciences, Michael helps clients turn complex innovation into commercially meaningful IP strategies. Passionate about supporting both early-stage research and established products, he combines technical precision with commercial insight and is trusted by innovators to deliver results that maximise the value of their IP.
Michael's practice is diverse: from building IP portfolios and strategies for start-ups and spin-outs to safeguarding high-value rights for products in clinical trials or already on the market. He works proactively to unlock and maximise IP opportunities from clinical data, ensuring clients capture value at every stage of development.
His work spans drafting and prosecuting patent applications, shaping global portfolio strategies, and handling contentious matters, including both defending and attacking patents in opposition proceedings before the European Patent Office (EPO). Known for his collaborative approach, strong scientific grounding, and dedicated commitment to client success, Michael provides pragmatic, practical advice that makes complex issues clear and actionable.
He leads the firm’s specialist team on patent term extensions and regulatory exclusivities, including supplementary protection certificates (SPCs). Recognised for his leadership in this area, Michael has coordinated high-profile SPC portfolios across Europe, including cases before the Court of Justice of the European Union (CJEU), and regularly shares practical insights through publications and international speaking engagements.
- Supporting early-stage research teams and spin-outs in capturing innovation and shaping IP strategies
- Leading EPO opposition proceedings, including complex multi-party disputes
- Devising global patent filing strategies and managing portfolios across multiple jurisdictions
- Coordinating prosecution of high-value SPC portfolios, including two cases referred to the CJEU
- UK and European Patent Attorney
- PhD, Biochemistry, University of Cambridge
- MSci, Natural Sciences (Biochemistry), University of Cambridge
I have worked with Michael Pears on several extremely important European oppositions - he has a great understanding of both European oppositions and complex biotechnology inventions - a winning combination - literally and figuratively!
Michael's collaborative approach, deep scientific understanding and strong mastery of European patent law make him a trusted partner for the most important European matters. He represents clientele effectively in both offensive and defensive oppositions, working hard to ensure they maintain protection of their patents with minimal amendments to the claims.
- IAM Patent 1000: Prosecution
- MIP IP STARS: Notable Practitioner
About Michael
Experience
Areas of expertise
Qualifications
Testimonials
Awards
How We Live Our Values: Collaboration
Collaboration is at the heart of how I work. I often sit down with colleagues from different technical backgrounds, and with litigators when needed, to make sure we are covering every angle and delivering the best possible outcome. Just as importantly, I work closely with clients to understand where they are headed and help shape IP strategies that genuinely support their business goals. It is a shared process, and that is what makes it effective.
In My Own Words
What drew me to patent law was the chance to apply my scientific background in a way that supports real-world innovation. I have always liked being close to the science, especially at the early stages when ideas are still taking shape and the direction is not yet clear. There is something rewarding about helping researchers and innovators turn that work into something protectable and commercially useful.
I also enjoy the strategic side of the role: building prosecution strategies and seeing them through across different jurisdictions. It is about making complex science work within a global IP framework that supports long-term goals. When it comes to oppositions, I find the mix of scientific depth and procedural nuance genuinely engaging. It is one of the few times you get to test a patent in a live setting, and that makes it both challenging and satisfying.
Ultimately, what keeps me motivated is seeing the impact of the work: whether it is a successful spin-out, a patent surviving opposition, or a portfolio that helps secure investment. Being part of that story, even behind the scenes, is what makes the job worthwhile.
Related News
The SPC Manufacturing Waiver in Practice: Legal Framework and Emerging Jurisprudence
.jpg)
UK SPC law changes from 1 January 2025: what you need to know
IAM Patent 1000: The World's Leading Patent Professionals 2025
No post-Brexit return to second medical use SPCs: Court of Appeal upholds refusal of Merck Serono SPC in the UK
CJEU clarifies SPC eligibility for combination products
CJEU swiftly deals with Genmab SPC application in reasoned order
Excipient or active ingredient? CJEU requested to rule on Articles 1(b) and 3(a) of the SPC Regulation